JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

Search

Certara Inc

Geschlossen

BrancheGesundheitswesen

6.17 0.82

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

6.12

Max

6.3

Schlüsselkennzahlen

By Trading Economics

Einkommen

-7.4M

-5.9M

Verkäufe

-968K

104M

KGV

Branchendurchschnitt

100.714

67.147

Gewinnspanne

-5.688

Angestellte

1,515

EBITDA

8.6M

32M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+44.07% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

11. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-77M

957M

Vorheriger Eröffnungskurs

5.35

Vorheriger Schlusskurs

6.17

Nachrichtenstimmung

By Acuity

50%

50%

186 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Certara Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

30. Apr. 2026, 23:08 UTC

Ergebnisse

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. Apr. 2026, 23:07 UTC

Ergebnisse

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. Apr. 2026, 22:20 UTC

Ergebnisse

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30. Apr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30. Apr. 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30. Apr. 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30. Apr. 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30. Apr. 2026, 23:22 UTC

Ergebnisse

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30. Apr. 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30. Apr. 2026, 22:52 UTC

Ergebnisse

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. Apr. 2026, 22:33 UTC

Ergebnisse

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30. Apr. 2026, 22:32 UTC

Ergebnisse

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30. Apr. 2026, 22:32 UTC

Ergebnisse

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30. Apr. 2026, 22:24 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30. Apr. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30. Apr. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30. Apr. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30. Apr. 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. Apr. 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30. Apr. 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30. Apr. 2026, 22:05 UTC

Ergebnisse

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30. Apr. 2026, 21:57 UTC

Ergebnisse

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30. Apr. 2026, 21:56 UTC

Ergebnisse

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30. Apr. 2026, 21:56 UTC

Ergebnisse

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30. Apr. 2026, 21:55 UTC

Ergebnisse

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30. Apr. 2026, 21:54 UTC

Ergebnisse

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30. Apr. 2026, 21:54 UTC

Ergebnisse

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30. Apr. 2026, 21:53 UTC

Ergebnisse

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30. Apr. 2026, 21:49 UTC

Ergebnisse

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30. Apr. 2026, 21:49 UTC

Ergebnisse

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Peer-Vergleich

Kursveränderung

Certara Inc Prognose

Kursziel

By TipRanks

44.07% Vorteil

12-Monats-Prognose

Durchschnitt 8.5 USD  44.07%

Hoch 10 USD

Tief 7 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Certara Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

3

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

11.27 / 12.79Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

186 / 347 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat